ARCA Historical Income Statement
ABIO Stock | USD 3.40 0.15 4.62% |
Historical analysis of ARCA Biopharma income statement accounts such as Interest Expense of 637.9 K, Selling General Administrative of 7.2 M or Total Revenue of 0.0 can show how well ARCA Biopharma performed in making a profits. Evaluating ARCA Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ARCA Biopharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining ARCA Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ARCA Biopharma is a good buy for the upcoming year.
ARCA |
About ARCA Income Statement Analysis
ARCA Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ARCA Biopharma shareholders. The income statement also shows ARCA investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
ARCA Biopharma Income Statement Chart
ARCA Biopharma Income Statement is one of the three primary financial statements used for reporting ARCA's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of ARCA Biopharma revenue and expense. ARCA Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, ARCA Biopharma's Interest Expense is very stable compared to the past year. As of the 19th of April 2024, Selling General Administrative is likely to grow to about 7.2 M, while Depreciation And Amortization is likely to drop about 105.5 K. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ARCA Biopharma. It is also known as ARCA Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from ARCA Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ARCA Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.At this time, ARCA Biopharma's Interest Expense is very stable compared to the past year. As of the 19th of April 2024, Selling General Administrative is likely to grow to about 7.2 M, while Depreciation And Amortization is likely to drop about 105.5 K.
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 13K | 675K | 1.8M | 1.9M | Interest Income | 13K | 675K | 1.8M | 1.9M |
ARCA Biopharma income statement Correlations
Click cells to compare fundamentals
ARCA Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ARCA Biopharma income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 261K | 28K | 13K | 114K | 111K | 105.5K | |
Interest Expense | 7K | 9K | 13K | 675K | 607.5K | 637.9K | |
Selling General Administrative | 4.0M | 4.8M | 5.5M | 5.8M | 6.3M | 7.2M | |
Gross Profit | (89K) | (93K) | (91K) | (114K) | (111K) | (105.5K) | |
Other Operating Expenses | 5.8M | 9.8M | 19.3M | 10.6M | 7.3M | 6.9M | |
Operating Income | (5.8M) | (9.8M) | (19.3M) | (10.6M) | (7.3M) | (7.7M) | |
Ebit | (5.8M) | (9.8M) | (19.3M) | (10.6M) | (7.3M) | (7.7M) | |
Research Development | 1.8M | 5.0M | 13.8M | 4.7M | 1.0M | 962.4K | |
Ebitda | (5.6M) | (9.7M) | (19.3M) | (10.5M) | (7.3M) | (7.7M) | |
Cost Of Revenue | 89K | 93K | 91K | 114K | 111K | 105.5K | |
Total Operating Expenses | 5.8M | 9.8M | 19.3M | 10.6M | 7.3M | 6.9M | |
Income Before Tax | (5.6M) | (9.7M) | (19.3M) | (9.9M) | (5.3M) | (5.6M) | |
Total Other Income Expense Net | 165K | 19K | 13K | 670K | 2.0M | 2.1M | |
Net Income | (5.5M) | (9.7M) | (19.2M) | (9.3M) | (5.3M) | (5.6M) | |
Income Tax Expense | (167K) | (9K) | (91K) | (670K) | (111K) | (116.6K) | |
Net Income From Continuing Ops | (5.5M) | (9.7M) | (19.3M) | (9.9M) | (5.4M) | (5.7M) | |
Non Operating Income Net Other | 167K | 162K | 172K | 28K | 32.2K | 30.6K | |
Net Income Applicable To Common Shares | (5.5M) | (9.7M) | (19.3M) | (9.9M) | (8.9M) | (9.4M) | |
Interest Income | 172K | 28K | 13K | 675K | 1.8M | 1.9M | |
Net Interest Income | 165K | 19K | 13K | 675K | 1.8M | 1.9M | |
Reconciled Depreciation | 89K | 93K | 91K | 114K | 117K | 100.8K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ARCA Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ARCA Biopharma's short interest history, or implied volatility extrapolated from ARCA Biopharma options trading.
Pair Trading with ARCA Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against ARCA Stock
0.85 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
0.68 | PFE | Pfizer Inc Report 7th of May 2024 | PairCorr |
0.48 | KZR | Kezar Life Sciences Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.
The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for ARCA Stock analysis
When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Return On Assets (0.11) | Return On Equity (0.14) |
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.